World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Microbiology 62 2829 2591 250 235 218 19331

Chloe Orkin publications per year

The chart shows the history of publications by Chloe Orkin between 2003 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Chloe Orkin published across 23 years, from 2003 to 2025, averaging 14.9 papers a year. Output peaked at 37 publications in 2025. 54 of the 343 publications appeared in the last two years.

No. of publications
10 20 30
Bar chart. Horizontal axis: year, 2003 to 2025. Vertical axis: number of publications, 0 to 37. Peak 37 publications in 2025. 2003: 1 publication 2004: 1 publication 2005: 1 publication 2006: 0 publications 2007: 8 publications 2008: 8 publications 2009: 11 publications 2010: 17 publications 2011: 15 publications 2012: 17 publications 2013: 14 publications 2014: 16 publications 2015: 21 publications 2016: 16 publications 2017: 13 publications 2018: 23 publications 2019: 19 publications 2020: 19 publications 2021: 24 publications 2022: 20 publications 2023: 25 publications 2024: 17 publications 2025: 37 publications
2003 2025

343 publications in total across all disciplines

View publications per year as a table
Chloe Orkin: publications per year, 2003 to 2025
Year Publications
2003 1
2004 1
2005 1
2006 0
2007 8
2008 8
2009 11
2010 17
2011 15
2012 17
2013 14
2014 16
2015 21
2016 16
2017 13
2018 23
2019 19
2020 19
2021 24
2022 20
2023 25
2024 17
2025 37
Total 343
Download as CSV

Chloe Orkin publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Chloe Orkin sits on this spectrum.

No. of scientists
50 100 150 200 250
Bar chart with 64 bars. Horizontal axis: publications, 55–64 to 679+. Vertical axis: number of scientists, 0 to 288. Most scientists, 288, have 135–144 publications. The last bar groups every scientist with 679 publications or more. The highlighted bar, 215–224 publications, is where this scientist sits. 55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 265 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 234 scientists 205–214 publications: 208 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55–64 publications 679+

This scientist: 218 publications — 56th percentile

56% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

View publications distribution as a table
Number of Microbiology scientists by publication count, Research.com 2026 ranking edition. Based on 5,513 ranked scientists.
Publications Scientists This scientist
55–64 8
65–74 29
75–84 55
85–94 112
95–104 137
105–114 190
115–124 235
125–134 234
135–144 288
145–154 265
155–164 264
165–174 253
175–184 276
185–194 190
195–204 234
205–214 208
215–224 198 218
225–234 155
235–244 161
245–254 160
255–264 146
265–274 139
275–284 148
285–294 115
295–304 96
305–314 88
315–324 106
325–334 65
335–344 76
345–354 64
355–364 62
365–374 65
375–384 61
385–394 34
395–404 44
405–414 36
415–424 35
425–434 29
435–444 33
445–454 34
455–464 25
465–474 26
475–484 20
485–494 19
495–504 16
505–514 17
515–524 23
525–534 14
535–544 14
545–554 18
555–564 12
565–574 7
575–584 9
585–594 9
595–604 9
605–614 7
615–624 9
625–634 7
635–644 4
645–654 5
655–664 6
665–674 7
675–678 3
679+ 99
Download as CSV

Chloe Orkin D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Chloe Orkin sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 88 bars. Horizontal axis: D-Index, 40 to 127+. Vertical axis: number of scientists, 0 to 162. Most scientists, 162, have 58 D-Index. The last bar groups every scientist with 127 D-Index or more. The highlighted bar, 62 D-Index, is where this scientist sits. 40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 112 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 123 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 94 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 62 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

View D-Index distribution as a table
Number of Microbiology scientists by D-index, Research.com 2026 ranking edition. Based on 5,513 ranked scientists.
D-Index Scientists This scientist
40 30
41 86
42 90
43 117
44 122
45 123
46 108
47 110
48 106
49 109
50 129
51 111
52 116
53 127
54 134
55 134
56 112
57 136
58 162
59 151
60 139
61 123
62 126 62
63 144
64 109
65 103
66 124
67 112
68 103
69 131
70 94
71 93
72 96
73 92
74 80
75 66
76 87
77 60
78 73
79 59
80 57
81 55
82 47
83 77
84 50
85 45
86 42
87 41
88 32
89 38
90 35
91 34
92 27
93 26
94 33
95 22
96 37
97 22
98 21
99 22
100 30
101 16
102 20
103 17
104 19
105 16
106 19
107 18
108 14
109 10
110 9
111 7
112 11
113 6
114 15
115 10
116 12
117 7
118 10
119 10
120 11
121 2
122 7
123 12
124 5
125 9
126 6
127+ 95
Download as CSV

Overview

Chloe Orkin is affiliated with Queen Mary University of London in the United Kingdom. Their research primarily spans the fields of medicine, immunology, and microbiology, with a significant focus on infectious diseases and virology.

The scientist's main fields of study include:

  • Medicine
  • Immunology and Microbiology

Within these areas, specific subfields of study covered are:

  • Infectious Diseases
  • Virology
  • Epidemiology
  • Molecular Biology
  • Emergency Medicine

The topics central to their work concentrate on HIV/AIDS and related infectious conditions, involving:

  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • HIV/AIDS Research and Interventions
  • Poxvirus research and outbreaks
  • HIV-related health complications and treatments
  • Bacillus and Francisella bacterial research
  • Herpesvirus Infections and Treatments

Chloe Orkin has contributed to numerous publications, including these recent papers:

  • "Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022" (2022) in New England Journal of Medicine
  • "Monkeypox" (2022) in The Lancet
  • "Mpox in people with advanced HIV infection: a global case series" (2023) in The Lancet
  • "Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection" (2020) in New England Journal of Medicine
  • "Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study" (2021) in The Lancet HIV

The frequent co-authors collaborating with Chloe Orkin include:

  • Vanessa Apea
  • Sara Paparini
  • Melanie Smuk
  • John Thornhill
  • Laura Waters

Publication venues where the scientist has regularly contributed include:

  • The Lancet HIV
  • bioRxiv (Cold Spring Harbor Laboratory)
  • HIV Medicine
  • Open Forum Infectious Diseases
  • SSRN Electronic Journal

Best Publications

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

    Paul E. Sax;Kristine M. Erlandson;Jordan E. Lake;Grace A. McComsey

  • Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy

    Margaret T. May;Mark Gompels;Valerie Delpech;Kholoud Porter

  • Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

    Francois Raffi;Anita Rachlis;Hans-Jürgen Stellbrink;W David Hardy

  • Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals

    Davide Corti;Johannes P. M. Langedijk;Andreas Hinz;Michael S. Seaman

  • Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study

    Margaret T May;Mark Gompels;Valerie Delpech;Kholoud Porter

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012

    Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  • Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study

    Hans-Jürgen Stellbrink;Chloe Orkin;Jose Ramon Arribas;Juliet Compston

  • Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

    Chloe Orkin;Keikawus Arasteh;Miguel Górgolas Hernández-Mora;Vadim Pokrovsky

  • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    Unknown

  • Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

    Joel Gallant;Adriano Lazzarin;Anthony Mills;Chloe Orkin

  • Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial

    Jürgen K. Rockstroh;Mark Nelson;Christine Katlama;Jay Lalezari

  • Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

    Anthony Mills;Jose R. Arribas;Jaime Andrade-Villanueva;Giovanni DiPerri

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.).

    Ian Williams;Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  • Brief Communication: Rituximab in HIV-associated Multicentric Castleman Disease

    Mark Bower;Tom Powles;Sarah Williams;Tom Newsom Davis

  • British HIV Association guidelines for the routine investigation and monitoring of adult HIV‐1‐infected individuals 2011

    D Asboe;C Aitken;M Boffito;C Booth

  • Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study

    Elchonon M. Berkowitz;Graeme Moyle;Hans-Jürgen Stellbrink;Dirk Schürmann

  • Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial†

    C Orkin;E DeJesus;H Khanlou;A Stoehr

  • Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

    Jean Michel Molina;Chloe Orkin;David M. Iser;Francisco Xavier Zamora

  • Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

    Samir K. Gupta;Frank A. Post;José R. Arribas;Joseph J. Eron

  • Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.

    Nicholas I. Paton;Ruth L. Goodall;David T. Dunn;Samuel Franzen

  • Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

    Jurgen Rockstroh;Karine Lacombe;Rolando M Viani;Chloe Orkin

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015

    Duncan Churchill;Laura Waters;Nadia Ahmed;Brian Angus

  • Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes

    Zobair M. Younossi;Maria Stepanova;Mark Sulkowski;Susanna Naggie

Frequent Co-Authors

Clifford Leen
Clifford Leen Western General Hospital
Martin Fisher
Martin Fisher University of Sussex
Caroline Sabin
Caroline Sabin University College London
Frank A. Post
Frank A. Post King's College London
David Dunn
David Dunn University College London
Richard Gilson
Richard Gilson University College London
Philippa Easterbrook
Philippa Easterbrook King's College London
Andrew N. Phillips
Andrew N. Phillips University College London
Brian Gazzard
Brian Gazzard St Bartholomew's Hospital
Mark Nelson
Mark Nelson University of Vermont

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring microbiology in the USA opens doors to diverse online degrees and career opportunities beyond traditional lab roles. For individuals facing unique challenges, there are accessible options to pursue education, such as degrees felons can get, which include many health-related programs offering a fresh start.

One promising route is becoming a functional medicine nurse practitioner, blending microbiology knowledge with patient care. Those interested can explore functional medicine nurse practitioner programs online, which provide specialized training in holistic health approaches.

For careers focused on healthcare data rather than direct patient interaction, medical coding presents a viable option. Understanding the cpc medical coding salary and career paths can help students leverage microbiology background into coding and billing roles crucial for health systems.

Similarly, health information management offers leadership potential combining science and administration. The health information management degree salary reflects strong demand, making it an attractive pathway for microbiology graduates interested in managing patient data and health records.

Best Scientists Citing Chloe Orkin

Trending Scientists

Recently Published Articles